Rankings · Price against the business
Most free cash flow per dollar of price
Graded A or B, ranked by free cash flow over the last twelve months divided by market value. Banks and insurers are left out, and yields above 50% are treated as data problems rather than bargains.
125 companies meet this test
Figures as of November 15, 2026
| # | Company | Grade | Free cash flow yield | P/E | Revenue growth | Market value |
|---|---|---|---|---|---|---|
| 1 | GMABGenmab A/S | B+ | 35.7% | 3.34 | +18% a year | $3.2B |
| 2 | NRIXNURIX THERAPEUTICS, INC. | A+ | 21.9% | 6.73 | — | $1.7B |
| 3 | BCRXBIOCRYST PHARMACEUTICALS, INC. | B | 18.7% | — | +45% a year | $2B |
| 4 | HRMYHARMONY BIOSCIENCES HOLDINGS, INC. | B+ | 17.5% | 11.14 | +22% a year | $2B |
| 5 | TAKTakeda Pharmaceutical Company Limited | A | 16.0% | 50.12 | +3% a year | $34.4B |
| 6 | GRFSGrifols SA | A | 14.8% | 33.82 | +7% a year | $5.9B |
| 7 | THCTENET HEALTHCARE CORP | A+ | 14.6% | 8.30 | +3% a year | $22.8B |
| 8 | SNYSanofi | B | 13.7% | 6.80 | +4% a year | $59B |
| 9 | ANIPANI PHARMACEUTICALS, INC | B+ | 13.3% | 14.26 | +32% a year | $1.5B |
| 10 | PCRXPACIRA BIOSCIENCES, INC. | B | 11.6% | 39.20 | +4% a year | $1.5B |
| 11 | ARDTArdent Health, Inc. | B | 11.3% | 17.28 | +6% a year | $2.5B |
| 12 | AMPHAmphastar Pharmaceuticals, Inc. | B+ | 11.1% | 13.41 | +7% a year | $1.3B |
| 13 | JAZZJazz Pharmaceuticals plc | A | 10.5% | 78.68 | +8% a year | $15.5B |
| 14 | UHSUNIVERSAL HEALTH SERVICES, INC. | B | 9.7% | 8.13 | +9% a year | $11.5B |
| 15 | ZBHZIMMER BIOMET HOLDINGS, INC. | B | 8.4% | 26.06 | +6% a year | $19.5B |
| 16 | VCYTVERACYTE, INC. | A+ | 8.2% | 15.80 | +19% a year | $2B |
| 17 | GMEDGLOBUS MEDICAL, INC. | B+ | 7.9% | 17.77 | +37% a year | $9.7B |
| 18 | GSKGSK plc | A+ | 7.9% | 13.56 | +4% a year | $108.9B |
| 19 | HALOHALOZYME THERAPEUTICS, INC. | A+ | 7.7% | 25.01 | +32% a year | $11.4B |
| 20 | IARTINTEGRA LIFESCIENCES HOLDINGS CORP | B | 7.7% | 84.71 | +2% a year | $1.1B |
| 21 | HLNHaleon plc | B+ | 7.5% | 18.50 | +1% a year | $41B |
| 22 | CAHCardinal Health, Inc. | B | 7.0% | 38.88 | +7% a year | $65B |
| 23 | EXELEXELIXIS, INC. | A+ | 6.9% | 20.66 | +12% a year | $16.8B |
| 24 | GILDGILEAD SCIENCES, INC. | A | 6.6% | — | +4% a year | $208.5B |
| 25 | ADUSAddus HomeCare Corp | B | 6.3% | 20.47 | +13% a year | $2.3B |
More rankings
A ranking orders companies by one stated measure. It is not a recommendation, and it says nothing about whether any share price is reasonable.